SEARCH

SEARCH BY CITATION

References

  • Bergquist J., Tarkowski A., Ewing A. and Ekman R. (1998) Catecholaminergic supression of immunocompetent cells. Immunol. Today 19, 562567.
  • Brown M. J. and Collery C. T. (1981) A specific radioenzymatic assay for dihydroxyphenylalanine (DOPA). Plasma dopa may be the precursor of urine free dopamine. Br. J. Clin. Pharmacol. 1, 7983.
  • Clinical and Laboratory Standards Institute. (2003) Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved Guideline. CLSI document EP6.
  • Clinical and Laboratory Standards Institute. (2004) Protocols for determination of limits of detection and limits of quantification; approved guideline. CLSI document EP17-A.
  • Clinical and Laboratory Standards Institute. (2005) Interference testing in clinical chemistry; approved guideline. Second edition. CLSI document EP7-A2, Vol. 25, No 27.
  • Clinical and Laboratory Standards Institute. (2008) Defining, establishing, and verifying reference intervals in clinical laboratory; approved guideline. CLSI document C28-A3.
  • Curtin F., Walker J. P. and Shulz P. (1996) Day-to-day intraindividual reliability and interindividual differences in monoamines excretion. J. Affect. Disord. 38, 173178.
  • Dalley J. W. and Everitt B. J. (2009) Dopamine receptors in the learning, memory and drug reward circuitry. Semin. Cell Dev. Biol. 20, 403410.
  • Davidson D. F., Grosset K. and Grosset D. (2007) Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites. Ann. Clin. Biochem. 44, 364368.
  • Derogatis L. R., Lipman R. S., Rickels K., Uhlenhuth E. H. and Covi L. (1974) The Hopkins Symptom Checklist (HSCL). A measure of primary symptom dimensions. Mod. Probl. Pharmacopsychiatry 7, 79110.
  • Dutton J., Copeland L. G., Playfer J. R. and Roberts N. B. (1993) Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor. Clin. Chem. 39, 629634.
  • Eisenhofer G., Kopin I. and Goldstein D. (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56, 331349.
  • Fibiger W., Singer G., Miller A. J., Armstrong S. and Datar M. (1984) Cortisol and catecholamines changes as functions of time-of-day and self-reported mood. Neurosci. Biobehav. Rev. 8, 523530.
  • Franco R., Pacheco R., Lluis C., Ahern G. P. and O'Connell P. (2007) The emergence of neurotransmitters ass immune modulators. Trends Immunol. 28, 400406.
  • Fraser C. G., Hyltoft P. P., Libeer J. C. and Ricos C. (1997) Proposals for setting generally applicable quality goals solely based on biology. Ann. Clin. Biochem. 34, 812.
  • Glass R. M., Allan T., Uhlenhut E. H., Kimball C. P. and Borinsetin D. I. (1978) Psychiatric screening in a medical clinic: an evaluation of a self-report inventory. Arch. Gen. Psychiatry 35, 11891195.
  • Goldstein D. (2010) Catecholamines 101. Clin. Auton. Res. 20, 331352.
  • Haroon E., Raison C. and Miller A. (2011) Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37, 137162.
  • Howland R. H. (2012) The Use of dopaminergic and stimulant drugs for the treatment of depression. J. Psychosoc. Nurs. Ment. Health Serv. 50, 1114.
  • Huisman H., Wynveen P. and Setter P. W. (2010a) Studies on the immune response and preparation of antibodies against a large panel of conjugated neurotransmitters and biogenic amines: specific polyclonal antibody response and tolerance. J. Neurochem. 112, 829841.
  • Huisman H., Wynveen P., Nichkova M. and Kellermann G. (2010b) Novel ELISAs for screening of the biogenic amines GABA, glycine, beta-phenylethylamine, agmatine, and taurine using one derivatization procedure of whole urine samples. Anal. Chem. 82, 65266533.
  • Isaac M. V., Serrano M., Ormazabal A., Peez-Duena B., Garcia-Cazorla A., Campsitol J. and Artuch R. (2008) Biochemical diagnosis of dopaminergic disturbances in pediatric patients: analysis of cerebrospinal fluid homovanillic acid and other biogenic amines. Clin. Biochem. 41, 13061315.
  • IsHak W. W., Davis M., Jeffrey J., Balayan K., Pechnick R. N., Bagot K. and Rapaport M. H. (2009) The role of dopaminergic agents in improving quality of life in major depressive disorder. Curr. Psychiatry Rep. 11, 503508.
  • de Jong W. H., de Vries E. G., Wolffenbuttel B. H. R. and Kema I. P. (2010a) Automated mass spectrometric analysis of urinary catecholamines using on-line solid phase extraction. J. Chromatogr. B 878, 15061512.
  • de Jong W. H., Post W., Kerstens M., de Vries E. G. and Kema I. P. (2010b) Elevated urinary free and deconjugated catecholamines after consumption of a catecholamine-rich diet. J. Clin. Endocrinol. Metab. 95, 28512855.
  • de Jong W. H., de Vries E. G. and Kema I. P. (2011) Current status and future developments of LC-MS/MS in clinical chemistry for quantification of biogenic amines. Clin. Biochem. 44, 95103.
  • Kienast T. and Heinz A. (2006) Dopamine and the diseased brain. CNS Neurol. Disord. Drug Targets 5, 109131.
  • Kim J., Jeon M., Paeng K. and Paeng I. (2008) Competitive enzyme-linked immunosorbent assay for determination of catecholamine, dopamine in serum. Anal. Chim. Acta 619, 8793.
  • Kim J., Park H., Ryu J., Jeon O. and Paeng I. (2010) Competitive enzyme-linked immunosorbent assay for a selective and sensitive determination of dopamine in the presence of ascorbic acid and uric acid. J. Immunoassay Immunochem. 31, 3344.
  • Knoll E. and Wisser H. (1984) Problems in the development of radioimmunoassay of catecholamines. J. Clin. Chem. Clin. Biochem. 22, 741749.
  • Kushnir M., Urry F., Frank E., Roberts W. and Shushan B. (2002) Analysis of catecholamines by positive-ion electrospray tandem mass spectrometry. Clin. Chem. 48, 323331.
  • Marc D. T., Ailts J. W., Ailts-Campeau D. C., Bull M. J. and Olson K. (2011) Neurotransmitters excreted in the urine as biomarkers of nervous system activity: validity and clinical applicability. Neurosci. Biobehav. Rev. 35, 635644.
  • Moriarty M., Lee A., O'Connell B., Kelleher A., Keeley H. and Furey A. (2011) Development of an LC-MS/MS method for the analysis of serotonin and related compounds in urine and the identification of a potential biomarker for attention deficit hyperactivity/hyperkinetic disorder. Anal. Bioanal. Chem. 401, 24812493.
  • Naranjo C. A., Tremblay L. K. and Busto U. E. (2001) The role of the brain reward system in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 781823.
  • Nichkova M., Huisman H., Wynveen P., Olson K., Marc D. and Kellermann G. (2012) Evaluation of a novel ELISA for serotonin: urinary serotonin as potential biomarker for depression. Anal. Bioanal. Chem. 402, 15931600.
  • Peaston R. and Weinkove C. (2004) Measurement of catecholamines and their metabolites. Ann. Clin. Biochem. 41, 1738.
  • Pussard E., Neveux M. and Guigueno N. (2009) Reference intervals for urinary catecholamines and metabolites from birth to adulthood. Clin. Biochem. 42, 536539.
  • Ricós C., García-Lario J. V., Alvarez V., Cava F. et al. (2012) BV database, and quality specifications for imprecision, bias and total error. http://www.westgard.com/biodatabase-2012-update.htm
  • Routh J. I., Bannow R. E., Fincham R. W. and Stoll J. L. (1971) Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy. Clin. Chem. 17, 867871.
  • Souza M. C. P., Rumpler W., Douglas L. W. and Howe J. (1998) Urinary catecholamne excretion in men and women: between- and within-subject variation. J. Nutr. Biochem. 9, 396401.
  • Tayebati S. K., Lokhandwala M. F. and Amenta F. (2011) Dopamine and vascular dynamics control: present status and future perspectives. Curr. Neurovasc. Res. 8, 246257.
  • Tsunoda M. (2006) Recent advances in methods for the analysis of catecholamines and metabolites. Anal. Bioanal. Chem. 386, 506514.
  • Westermann J., Hubl W., Kaiser N. and Salewski L. (2002) Simple, rapid and sensitive cetermination of epinephrine and norepinephrine in urine and plasma by non-competitive enzyme immunoassay, compared with HPLC method. Clin. Lab. 48, 6171.
  • Westernik B. H. C. and ten Kate N. (1986) 24 h excretion patterns of free, conjugated and methylated catecholamines in man. J. Clin. Chem. Clin. Biochem. 24, 513519.
  • Willner P. (1983) Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res. Rev. 6, 211224.